Trial · NCT02879448
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Primary Safety Endpoint: Composite Endpoint Rate of Procedure-related Complications, or All-cause Death or Major Bleeding (Defined as Type 3 or Greater Based on the Bleeding Academic Research Consortium (BARC) Definition) (Non-inferiority Analysis) | Amulet | 14.5 | Percentage of participants | ||
Primary Safety Endpoint: Composite Endpoint Rate of Procedure-related Complications, or All-cause Death or Major Bleeding (Defined as Type 3 or Greater Based on the Bleeding Academic Research Consortium (BARC) Definition) (Non-inferiority Analysis) | WATCHMAN (Control) | 14.7 | Percentage of participants | ||
| Primary Effectiveness Endpoint: Composite Rate of Ischemic Stroke or Systemic Embolism (Non-inferiority Analysis) | Amulet | 2.8 | Percentage of participants | ||
| Primary Effectiveness Endpoint: Composite Rate of Ischemic Stroke or Systemic Embolism (Non-inferiority Analysis) | WATCHMAN (Control) | 2.8 | Percentage of participants | ||
| Mechanism of Action Primary Endpoint: Rate of Device Closure, by the Echocardiography Core Lab (Non-inferiority Analysis) | Amulet | 98.9 | Percentage of participants | ||
| Mechanism of Action Primary Endpoint: Rate of Device Closure, by the Echocardiography Core Lab (Non-inferiority Analysis) | WATCHMAN (Control) | 96.8 | Percentage of participants | ||
| Composite Rate of All Stroke, Systemic Embolism, or Cardiovascular/Unexplained Death (Non-inferiority Analysis) | Amulet | 5.6 | Percentage of participants | ||
| Composite Rate of All Stroke, Systemic Embolism, or Cardiovascular/Unexplained Death (Non-inferiority Analysis) | WATCHMAN (Control) | 7.7 | Percentage of participants | ||
| Rate of Major Bleeding (Superiority Analysis) | Amulet | 11.6 | Percentage of participants | ||
| Rate of Major Bleeding (Superiority Analysis) | WATCHMAN (Control) | 12.3 | Percentage of participants | ||
Superiority Test of Primary Safety Endpoint: Composite Endpoint Rate of Procedure-related Complications, or All-cause Death or Major Bleeding (Defined as Type 3 or Greater Based on the Bleeding Academic Research Consortium (BARC) Definition) | Amulet | 14.5 | percentage of participants | ||
Superiority Test of Primary Safety Endpoint: Composite Endpoint Rate of Procedure-related Complications, or All-cause Death or Major Bleeding (Defined as Type 3 or Greater Based on the Bleeding Academic Research Consortium (BARC) Definition) | WATCHMAN (Control) | 14.7 | percentage of participants | ||
| Superiority Test of Primary Effectiveness Endpoint: Composite Rate of Ischemic Stroke or Systemic Embolism | Amulet | 2.8 | Percentage of participants | ||
| Superiority Test of Primary Effectiveness Endpoint: Composite Rate of Ischemic Stroke or Systemic Embolism | WATCHMAN (Control) | 2.8 | Percentage of participants | ||
| Superiority Test of Primary Mechanism of Action Endpoint: Rate of Device Closure, by the Echocardiography Core Lab | Amulet | 98.9 | Percentage of participants | ||
| Superiority Test of Primary Mechanism of Action Endpoint: Rate of Device Closure, by the Echocardiography Core Lab | WATCHMAN (Control) | 96.8 | Percentage of participants | ||
| Composite Rate of Ischemic Stroke and Systemic Embolism | Amulet | 7.4 | percentage of participants | ||
| Composite Rate of Ischemic Stroke and Systemic Embolism | WATCHMAN (Control) | 7.1 | percentage of participants | ||
| Composite Rate of Stroke, Systemic Embolism, or CV/Unexplained Death | Amulet | 20.3 | percentage of participants | ||
| Composite Rate of Stroke, Systemic Embolism, or CV/Unexplained Death | WATCHMAN (Control) | 20.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02879448/results